Journal of Substance Abuse Treatment
Volume 38, Issue 4 , Pages 403-407 , June 2010

Prospective comparative assessment of buprenorphine overdose with heroin and methadone: Clinical characteristics and response to antidotal treatment

  • Bruno Mégarbane, M.D., Ph.D.

      Affiliations

    • Réanimation Médicale et Toxicologique, Hôpital Lariboisière, Université Paris-Diderot, Paris, France
    • INSERM U705, CNRS, UMR 8206, Université Paris-Descartes, Paris, France
    • Corresponding Author InformationCorresponding author. Réanimation Médicale et Toxicologique, Hôpital Lariboisière, 2 rue Ambroise Paré, 75010 Paris, France. Tel.: +33 1 49 95 64 91; fax: +33 1 49 95 65 78.
    • ,
  • Anne Buisine, Pharm.D.

      Affiliations

    • Laboratoire de Toxicologie, Hôpital Lariboisière, Université Paris-Diderot Paris, France
    • ,
  • Frédéric Jacobs, M.D.

      Affiliations

    • Réanimation Médicale, Hôpital Antoine Béclère, Université Paris-Sud, Clamart, France
    • ,
  • Dabor Résière, M.D.

      Affiliations

    • Réanimation Médicale et Toxicologique, Hôpital Lariboisière, Université Paris-Diderot, Paris, France
    • ,
  • Lucie Chevillard, Ph.D.

      Affiliations

    • INSERM U705, CNRS, UMR 8206, Université Paris-Descartes, Paris, France
    • ,
  • Eric Vicaut, M.D., Ph.D.

      Affiliations

    • Unité de Recherche Clinique et Biostatistiques, Hôpital Fernand Widal, Université Paris-Diderot, Paris, France
    • ,
  • Frédéric J. Baud, M.D.

      Affiliations

    • Réanimation Médicale et Toxicologique, Hôpital Lariboisière, Université Paris-Diderot, Paris, France
    • INSERM U705, CNRS, UMR 8206, Université Paris-Descartes, Paris, France

Received 11 September 2009 ,Revised 6 January 2010 ,Accepted 22 January 2010.

References 

  1. Berkowitz BA. The relationship of pharmacokinetics to pharmacological activity: Morphine, methadone and naloxone. Clinical Pharmacokinetics. 1976;1:219–230
  2. Boyd J, Randell T, Luurila H, Kuisma M. Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiologica Scandinavica. 2003;47:1031–1033
  3. Cowan A, Dowey J, Harry E. The animal pharmacology of buprenorphine, an oripavine analgesic agent. British Journal of Pharmacology. 1977;60:547–554
  4. Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. British Journal of Anaesthesia. 2005;94:825–834
  5. Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. British Journal of Anaesthesia. 2006;96:627–632
  6. Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Current Psychiatry Reports. 2007;9:358–364
  7. Gal TJ. Naloxone reversal of buprenorphine-induced respiratory depression. Clinical Pharmacology & Therapeutics. 1989;45:66–71
  8. Gibson AE, Degenhardt LJ. Mortality related to pharmacotherapies for opioid dependence: A comparative analysis of coronial records. Drug and Alcohol Review. 2007;26:405–410
  9. Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O'Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction. 2008;103:462–468
  10. Gueye PN, Borron SW, Risede P, Monier C, Buneaux F, Debray M, et al. Lack of effect of single high doses of buprenorphine on arterial blood gases in the rat. Toxicological Sciences. 2001;62:148–154
  11. Gueye PN, Borron SW, Risede P, Monier C, Buneaux F, Debray M, et al. Buprenorphine and midazolam act in combination to depress respiration in rats. Toxicological Sciences. 2002;65:107–114
  12. Gueye PN, Hoffman JR, Taboulet P, Vicaut E, Baud FJ. Empiric use of flumazenil in comatose patients: Limited applicability of criteria to define low risk. Annals of Emergency Medicine. 1996;27:730–735
  13. Gueye PN, Lofaso F, Borron SW, Mellerio F, Vicaut E, Harf A, et al. Mechanism of respiratory insufficiency in pure or mixed drug-induced coma involving benzodiazepines. Journal of Toxicology Clinical Toxicology. 2002;40:35–47
  14. Gueye PN, Mégarbane B, Borron SW, Adnet F, Galliot-Guilley M, Ricordel I, et al. Trends in opiate and opioid poisonings in addicts in north-east Paris and suburbs, 1995-99. Addiction. 2002;97:1295–1304
  15. Hayes BD, Klein-Schwartz W, Doyon S. Toxicity of buprenorphine overdoses in children. Pediatrics. 2008;121:e782–e786
  16. Hoffman JR, Schriger DL, Luo JS. The empiric use of naloxone in patients with altered mental status: A reappraisal. Annals of Emergency Medicine. 1991;20:246–252
  17. Kintz P. Deaths involving buprenorphine: A compendium of French cases. Forensic Science International. 2001;121:65–69
  18. Krantz MJ, Mehler PS. Treating opioid dependence. Growing implications for primary care. Archives of Internal Medicine. 2004;164:277–288
  19. Lai SH, Yao YJ, Lo DS. A survey of buprenorphine related deaths in Singapore. Forensic Science International. 2006;162:80–86
  20. Mathieu-Nolf M, Babé MA, Coquelle-Couplet V, Billaut C, Nisse P, Mathieu D. Flumazenil use in an emergency department: A survey. Journal of Toxicology Clinical Toxicology. 2001;39:15–20
  21. Mégarbane B, Hreiche R, Pirnay S, Marie N, Baud FJ. Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxicology Reviews. 2006;25:79–85
  22. Mégarbane B, Pirnay S, Borron SW, Trout H, Monier C, Risède P, et al. Flunitrazepam does not alter cerebral distribution of buprenorphine in the rat. Toxicology Letters. 2005;157:211–219
  23. Nielsen S, Dietze P, Cantwell K, Lee N, Taylor D. Methadone- and buprenorphine-related ambulance attendances: A population-based indicator of adverse events. Journal of Substance Abuse Treatment. 2008;35:457–461
  24. O'Brien CP. A 50-year-old woman addicted to heroin: Review of treatment of heroin addiction. Journal of the American Medical Association. 2008;300:314–321
  25. Ødegård E, Amundsen EJ, Kielland KB. Fatal overdoses and deaths by other causes in a cohort of Norwegian drug abusers—A competing risk approach. Drug Alcohol Dependence. 2007;89:176–182
  26. Pirnay S, Borron SW, Giudicelli CP, Tourneau J, Baud FJ, Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: Analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction. 2004;99:978–988
  27. Pirnay S, Megarbane B, Declèves X, Risède P, Borron SW, Bouchonnet S, et al. Buprenorphine alters desmethylflunitrazepam disposition and flunitrazepam toxicity in rats. Toxicological Sciences. 2008;106:64–73
  28. Soyka M, Apelt SM, Lieb M, Wittchen HU. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: A nationally representative cohort study in 2694 patients. Journal of Clinical Psychopharmacology. 2006;26:657–660
  29. Soyka M, Penning R, Wittchen U. Fatal poisoning in methadone and buprenorphine treated patients—Are there differences?. Pharmacopsychiatry. 2006;39:85–87
  30. Sporer KA. Buprenorphine: A primer for emergency physicians. Annals of Emergency Medicine. 2004;43:580–584
  31. Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: A report on 20 fatalities. Journal of Analytical Toxicology. 1998;22:430–434
  32. van Dorp E, Yassen A, Sarton E, Romberg R, Olofsen E, Teppema L, et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology. 2006;105:51–57
  33. van Dorp EL, Yassen A, Dahan A. Naloxone treatment in opioid addiction: The risks and benefits. Expert Opinion in Drug Safety. 2007;6:125–132
  34. Vocci FJ, Acri J, Elkashef A. Medication development for addictive disorders: The state of the science. American Journal of Psychiatry. 2005;162:1432–1440
  35. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology & Therapeutics. 1994;55:569–580
  36. Yassen A, Olofsen E, van Dorp E, Sarton E, Teppema L, Danhof M, et al. Mechanism-based pharmacokinetic–pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone: A study in healthy volunteers. Clinical Pharmacokinetics. 2007;46:965–980

 Ethics approval: The ethics committee of the French Society of Critical Care Medicine, Société de Réanimation en Langue Française, has approved the study.

PII: S0740-5472(10)00014-0

doi: 10.1016/j.jsat.2010.01.006

Journal of Substance Abuse Treatment
Volume 38, Issue 4 , Pages 403-407 , June 2010

Article Tools